Early-stage, high-risk/high-impact tech development to create novel molecular/cellular analysis tools for cancer research. Part of NCI’s IMAT program. (FON: RFA-CA-25-001)
Eligibility Criteria:
-
U.S. and foreign organizations eligible; multiple PD/PIs allowed.
-
Projects must focus on novel tech development (not hypothesis-driven biology) and include quantitative performance measures.
-
No clinical trials; non-responsive: biomarker discovery/validation, drug development, whole-body imaging, software-only projects.
Funding Details:
-
Up to USD 150,000 USD direct costs/year.
-
Project period up to 3 years.
-
~17 awards anticipated in FY 2026.
Deadline:
-
Application due: April 4, 2025; October 3, 2025 (5:00 PM local).
Where to Go for Further Information:
-
Scientific contact: Kelly Crotty, PhD — [email protected].
-
General help: [email protected].